![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » AZ Relinquishes Rights to Opioid Constipation Treatment
AZ Relinquishes Rights to Opioid Constipation Treatment
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
AstraZeneca announced last week its intention to hand over rights to Moventig — a treatment for opioid-induced constipation — to Kyowa subsidiary ProStrakan Group for $70 million.
Under the agreement, ProStrakan will pay AstraZeneca tiered double-digit royalties on sales and milestones for the product, which is known as Movantik in the U.S.
Upcoming Events
-
21Oct